Navigation Links
Scientists Learn How Cancer Drugs Cause Hypertension
Date:8/5/2009

Finding points to ways to control blood pressure, researchers say

WEDNESDAY, Aug. 5 (HealthDay News) -- A new study reveals why high blood pressure develops in up to one-third of cancer patients who take drugs to block the formation of blood vessels that feed tumors.

"Anti-angiogenesis drugs like Avastin, Sutent or Nexavar inhibit an important substance called vascular endothelial growth factor [VEGF] that stimulates the creation of new vessels that support malignant growth," senior study author Dr. Thomas Coffman, a professor of medicine, cell biology and immunology at Duke University Medical Center in Durham, N.C., said in a school news release. "Our studies in mice show that blocking VEGF causes hypertension because it disrupts an important biological system -- the nitric oxide pathway that regulates blood vessel health."

The researchers used an antibody to block an important VEGF receptor called VEGFR2. After about a week, the mice that received a high dose of the antibody showed a "rapid and sustained" increase in blood pressure.

"The higher doses of anti-angiogenesis drugs that patients need to keep their cancers from growing translate into a significant increase in risk for hypertension and, by extension, for cardiovascular complications," Coffman said.

The study appears online Aug. 3 in the journal Hypertension.

Cancer patients are living longer, Coffman noted. This means that hypertension and other side effects that might once have seemed less important must now be taken more seriously.

"Long-term hypertension can have serious consequences," Coffman said.

For many cancer patients taking anti-angiogenesis drugs, hypertension is controlled with traditional blood pressure medications, said Dr. Herbert Hurwitz, a medical oncologist at Duke.

"However, these new findings are important since they point to specific ways to better protect against the risks of
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Scientists Probe Sepsis Deadly Secrets
3. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
4. Scientists Develop Natural Protection for Stored Foods
5. Scientists detect presence of marburg virus in african fruit bats
6. Scientists Spot Brains Free Will Center
7. Scientists ID Likely Culprit in Popcorn Lung
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. Scientists, physicians present latest findings in personalized cancer treatment and prevention
11. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scientists Learn How Cancer Drugs Cause Hypertension
(Date:7/29/2014)... Nevada (PRWEB) July 29, 2014 The Board ... Holland & Hart LLP ’s Connie Akridge ... She currently serves as President of the Foundation. Akridge served ... , Akridge is a partner at Holland & Hart in ... litigation and regulatory/administrative matters to insurance and healthcare clients for ...
(Date:7/29/2014)... New high priced hepatitis C drugs ... a projected $2.9 to $5.8 billion next year, according ... released today by the Pharmaceutical Care Management Association (PCMA). ... by as much as 8.6 percent in 2015 as ... and Olysio. , The study finds that the majority ...
(Date:7/29/2014)... 29, 2014 The Law Offices of Michael ... of Hope, a non-profit organization providing grief camps for kids, ... anguish and suffering our clients experience from the death of ... support an organization like Stepping Stones of Hope, as they ... Stepping Stones of Hope also includes a monthly support group ...
(Date:7/29/2014)... sufferers to record the severity and regularity of their ... research study. , A new approach to the treatment ... their triggers and is being led by Professor Paul ... program. , He has developed an approach designed to ... headaches called Learning to Cope with Triggers (LCT). , ...
(Date:7/29/2014)... cancer is to surgically remove the tumor. The Achilles ... may fail to extract the entire tumor, leading to ... at the University of Pennsylvania have established a new ... the patient, increasing the likelihood of a positive outcome. ... in cancerous tissues much more so than normal tissues. ...
Breaking Medicine News(10 mins):Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:The Law Offices of Michael Cordova is Sponsoring Stepping Stones of Hope, a Non-Profit Organization Providing Grief Camps for Kids, Teens, Adults, and Families 2Health News:Penn team makes cancer glow to improve surgical outcomes 2Health News:Penn team makes cancer glow to improve surgical outcomes 3
... HILL, N.C., Feb. 19 With sales forces ... the constant,demand for rep time, winning a place ... response, leading pharma companies are relying on,specialized training ... process within the hospital environment, according to recent,research ...
... WYE ),announced today that The Honorable Stuart R. ... Maryland, has granted Wyeth,s motion for,summary judgment in the ... al -- an alleged vaccine injury case claiming that ... autistic., Previously, the Court had granted Wyeth,s motion ...
... PARK, Fla., Feb. 19 Transitionz Wellness,Boutique is ... or adult, who,is a cancer survivor, is going ... is trying to get well, and we are ... of the best products and services,including wigs, hats, ...
... A new technique developed by a University of Central ... bacterial infections patients have so they can be treated ... strains resistant to many drugs emerge, it becomes more ... would most effectively treat them. Such quick identifications become ...
... new study released,today found that pending congressional legislation ... technologies would likely result,in increased prices and "provide ... released today at the National Press Club by ... and senior fellow at,the American Enterprise Institute, and ...
... response to recent media,reports, Roche would like to reaffirm ... medication for the 2007-2008,flu season, and that physicians and ... flu strikes., Some news reports have indicated "shortages" ... in place to ensure that Tamiflu is readily,available. If ...
Cached Medicine News:Health News:Building an Effective Sales Force to Serve the U.S. Hospital Market 2Health News:Wyeth Wins Thimerosal-Autism Case in Maryland Court 2Health News:Wyeth Wins Thimerosal-Autism Case in Maryland Court 3Health News:Transitionz Wellness Boutique Launches with Grand Opening Discounts 2Health News:UCF technique promises to aid doctor's ability to identify, treat bacterial infections 2Health News:New Report Finds Mandatory Price Disclosure for Med Tech Would Likely Increase Prices 2Health News:Press Statement: Roche Affirms That Tamiflu(R) is in Ample Supply Nationwide 2
(Date:7/29/2014)... , July 29, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... participating in two healthcare conferences during the third quarter, ... Morgan Stanley Global Healthcare 2014 Conference.  Alexza,s corporate presentation ... The details on each event are below: ... 11, 2014 in Boston , MA.  ...
(Date:7/29/2014)... GLENWOOD, Ill. , July 29, 2014  Landauer, ... in personal and environmental radiation measurement and monitoring, outsourced ... will release financial results for the fiscal third quarter ... 2014. The Company will host a ... at 9:00 a.m. Central Time (10 a.m. Eastern Time). ...
(Date:7/29/2014)... (NYSE: CVD ) today reported results for ... was $639 million, representing 8.0% growth from the second ... reported earnings of $0.29 per diluted share in the ... diluted share of $0.95, up 21.5% over the second ... charges totaling $52.6 million, or $0.61 per share, and ...
Breaking Medicine Technology:Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24
... Spaced, Expandable, Multichannel Pipettor The ... boosts productivity with an industry breakthroughequal tip ... of a slide rod. This innovation allows ... between vessels with different configurations. Adjustable ...
... Expandable, Multichannel Pipettor The Equalizer ... productivity with an industry breakthroughequal tip spacings ... a slide rod. This innovation allows the ... vessels with different configurations. Adjustable and ...
... for Unparalleled Comfort Pick one of our ... Notice the trigger and ejector positionsright where they ... pipettors are ergonomically designed to help avoid repetitive ... Productivity In The Palm Of Your Hand ...
... Ergonomic Design for Unparalleled Comfort Pick one ... the balance. Notice the trigger and ejector positionsright ... because our pipettors are ergonomically designed to help ... of pipetting. Productivity In The Palm Of ...
Medicine Products: